Marina Simão Bertani
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Marina Simão Bertani has a total of 138 co-authors. Here are the top co-authors by number of shared publications:
- Luigi Benussi
INFN Laboratori Nazionali di Frascati
2 shared publications - A. Andronenkov
INFN Sezione di Bari, via Amendola 173, Bari, Italy
1 shared publication - A. Dimitrov
12 University of Sofia, Sofia, Bulgaria
1 shared publication A. Pantaleo
INFN Sezione di Bari, via Amendola 173, Bari, Italy
1 shared publicationA. Panzarasa
INFN Sezione di Pavia, via Bassi 6, Pavia, Italy
1 shared publicationA. Ranieri
Istituto Nazionale di Fisica Nucleare of Bari, Italy
1 shared publication
Latest Publications
- Open Access
- 18 November 2025
- Published by Federação das Associações de Ginecologia e Obstetrícia in Revista Brasileira de Ginecologia e Obstetrícia
- Vol. 47
Levothyroxine in euthyroid pregnant women with thyroid peroxidase antibody: a systematic review and meta-analysis of randomized controlled trials
Objective: Thyroid peroxidase antibody (TPOAb) is a prevalent condition amongst women of reproductive age and has been associated with adverse pregnancy outcomes. However, there is currently no proven treatment for euthyroid pregnant women with TPOAb. Therefore, we aimed to investigate the efficacy of levothyroxine treatment in this population. Methods: We searched PubMed, Embase and Cochrane Central from inception to or randomized controlled trials (RCTs) comparing levothyroxine with placebo or no treatment in euthyroid pregnant women who were positive for TPOAb. Our main outcomes were miscarriage, preterm birth, and live birth. We performed subgroup analysis based on recurrent pregnancy loss (RPL). Results: We included 8 RCTs comprising 1,645 pregnant women, of whom 814 (49.5%) were randomized to receive levothyroxine. Pregnant women treated with levothyroxine had significantly lower miscarriages (RR 0.78; 95% CI 0.63-0.98; p=0.035). No significant difference was found regarding pre-term birth (RR 0.78; 95% CI 0.55-1.13; p=0.189) and live birth (RR 1.05; 95% CI 0.99-1.12; p=0.097). Our subgroup analysis demonstrated a significant interaction (p=0.048) between patients with RPL (RR 1.21; 95% CI 1.03-1.42; p=0.023) and no RPL (RR 1.00; 95% CI 0.92-1.09; p=0.922). Conclusion: Levothyroxine reduced miscarriage in pregnant women with TPOAb and improved live birth rate when associated with RPL. Our subgroup analysis also provides evidence that levothyroxine may have a higher benefit for patients with a history of RPL.
- 18 November 2025
- Published by Federação das Associações de Ginecologia e Obstetrícia in Revista Brasileira de Ginecologia e Obstetrícia
- Vol. 47
Open AccessLevothyroxine in euthyroid pregnant women with thyroid peroxidase antibody: a systematic review and meta-analysis of randomized controlled trials
Objective: Thyroid peroxidase antibody (TPOAb) is a prevalent condition amongst women of reproductive age and has been associated with adverse pregnancy outcomes. However, there is currently no proven treatment for euthyroid pregnant women with TPOAb. Therefore, we aimed to investigate the efficacy of levothyroxine treatment in this population. Methods: We searched PubMed, Embase and Cochrane Central from inception to or randomized controlled trials (RCTs) comparing levothyroxine with placebo or no treatment in euthyroid pregnant women who were positive for TPOAb. Our main outcomes were miscarriage, preterm birth, and live birth. We performed subgroup analysis based on recurrent pregnancy loss (RPL). Results: We included 8 RCTs comprising 1,645 pregnant women, of whom 814 (49.5%) were randomized to receive levothyroxine. Pregnant women treated with levothyroxine had significantly lower miscarriages (RR 0.78; 95% CI 0.63-0.98; p=0.035). No significant difference was found regarding pre-term birth (RR 0.78; 95% CI 0.55-1.13; p=0.189) and live birth (RR 1.05; 95% CI 0.99-1.12; p=0.097). Our subgroup analysis demonstrated a significant interaction (p=0.048) between patients with RPL (RR 1.21; 95% CI 1.03-1.42; p=0.023) and no RPL (RR 1.00; 95% CI 0.92-1.09; p=0.922). Conclusion: Levothyroxine reduced miscarriage in pregnant women with TPOAb and improved live birth rate when associated with RPL. Our subgroup analysis also provides evidence that levothyroxine may have a higher benefit for patients with a history of RPL.
- Open Access
- 1 August 2013
- Published by Elsevier in Nuclear Instruments and Methods in Physics Research Section A: Accelerators, Spectrometers, Detectors and Associated Equipment
- Vol. 718, 118-120
The zero degree detector at BESIII
- 1 August 2013
- Published by Elsevier in Nuclear Instruments and Methods in Physics Research Section A: Accelerators, Spectrometers, Detectors and Associated Equipment
- Vol. 718, 118-120
Open AccessThe zero degree detector at BESIII
- 1 October 2009
- Published by World Scientific Pub Co Pte Ltd
- p. 308-313
THE SEARCH FOR ANTIKAON NUCLEAR BOUND STATES, RECENT RESULTS FROM FINUDA
- 1 October 2009
- Published by World Scientific Pub Co Pte Ltd
- p. 308-313
THE SEARCH FOR ANTIKAON NUCLEAR BOUND STATES, RECENT RESULTS FROM FINUDA
- 1 May 2009
- Published by Elsevier in Nuclear Instruments and Methods in Physics Research Section A: Accelerators, Spectrometers, Detectors and Associated Equipment
- Vol. 602 (3) , 696-699
Resistive plate chamber commissioning and performance in CMS
- 1 May 2009
- Published by Elsevier in Nuclear Instruments and Methods in Physics Research Section A: Accelerators, Spectrometers, Detectors and Associated Equipment
- Vol. 602 (3) , 696-699
Resistive plate chamber commissioning and performance in CMS